United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $533.90, for a total transaction of $5,072,050.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $21,629,890.70. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

United Therapeutics stock opened at $540.02 on Wednesday. The firm has a 50 day simple moving average of $488.31 and a 200-day simple moving average of $465.54. The stock has a market capitalization of $23.67 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.19 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Royal Bank Of Canada boosted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $548.09.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the company. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.